These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

223 related items for PubMed ID: 3106653

  • 1. Bacillus Calmette-Guerin for treatment of superficial transitional cell carcinoma of the bladder in patients who have failed thiotepa and/or mitomycin C.
    Soloway MS, Perry A.
    J Urol; 1987 May; 137(5):871-3. PubMed ID: 3106653
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Bacillus Calmette-Guerin versus doxorubicin versus thiotepa: a randomized prospective study in 202 patients with superficial bladder cancer.
    Martínez-Piñeiro JA, Jiménez León J, Martínez-Piñeiro L, Fiter L, Mosteiro JA, Navarro J, García Matres MJ, Cárcamo P.
    J Urol; 1990 Mar; 143(3):502-6. PubMed ID: 2106041
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Results of 6 weekly intravesical bacillus Calmette-Guerin instillations on the treatment of superficial bladder tumors.
    Kavoussi LR, Torrence RJ, Gillen DP, Hudson MA, Haaff EO, Dresner SM, Ratliff TL, Catalona WJ.
    J Urol; 1988 May; 139(5):935-40. PubMed ID: 3361667
    [Abstract] [Full Text] [Related]

  • 7. Intravesical bacillus Calmette-Guerin therapy for superficial bladder cancer: effect of bacillus Calmette-Guerin viability on treatment results.
    Kelley DR, Ratliff TL, Catalona WJ, Shapiro A, Lage JM, Bauer WC, Haaff EO, Dresner SM.
    J Urol; 1985 Jul; 134(1):48-53. PubMed ID: 3892051
    [Abstract] [Full Text] [Related]

  • 8. Experience with bacillus Calmette-Guerin in patients with superficial bladder carcinoma.
    Brosman SA.
    J Urol; 1982 Jul; 128(1):27-30. PubMed ID: 6809960
    [Abstract] [Full Text] [Related]

  • 9. Long-term followup of patients treated with 1 or 2, 6-week courses of intravesical bacillus Calmette-Guerin: analysis of possible predictors of response free of tumor.
    Coplen DE, Marcus MD, Myers JA, Ratliff TL, Catalona WJ.
    J Urol; 1990 Sep; 144(3):652-7. PubMed ID: 2388321
    [Abstract] [Full Text] [Related]

  • 10. Superficial bladder cancer treated with bacillus Calmette-Guerin: a multivariate analysis of factors affecting tumor progression.
    Herr HW, Badalament RA, Amato DA, Laudone VP, Fair WR, Whitmore WF.
    J Urol; 1989 Jan; 141(1):22-9. PubMed ID: 2908949
    [Abstract] [Full Text] [Related]

  • 11. Comparison of the efficacy of intravesical Bacillus Calmette-Guérin with thiotepa, mitomycin C, poly I:C/poly-L-lysine and cis platinum in murine bladder cancer.
    Shapiro A, Ratliff TL, Oakley DM, Catalona WJ.
    J Urol; 1984 Jan; 131(1):139-42. PubMed ID: 6418894
    [Abstract] [Full Text] [Related]

  • 12. Intravesical chemotherapy: how effective is it?
    Heney NM.
    Urology; 1988 Mar; 31(3 Suppl):17-9. PubMed ID: 3126591
    [Abstract] [Full Text] [Related]

  • 13. Bacillus Calmette-Guerin immunotherapy for bladder cancer.
    Lamm DL.
    J Urol; 1985 Jul; 134(1):40-7. PubMed ID: 3892050
    [Abstract] [Full Text] [Related]

  • 14. The management of superficial bladder tumors and carcinoma in situ with intravesical bacillus Calmette-Guerin.
    deKernion JB, Huang MY, Lindner A, Smith RB, Kaufman JJ.
    J Urol; 1985 Apr; 133(4):598-601. PubMed ID: 3981707
    [Abstract] [Full Text] [Related]

  • 15. Intravesical bacillus Calmette-Guerin therapy for in situ transitional cell carcinoma involving the prostatic urethra.
    Bretton PR, Herr HW, Whitmore WF, Badalament RA, Kimmel M, Provet J, Oettgen HF, Melamed MR, Fair WR.
    J Urol; 1989 Apr; 141(4):853-6. PubMed ID: 2926879
    [Abstract] [Full Text] [Related]

  • 16. Long-term results of intravesical bacillus Calmette-Guerin therapy for superficial bladder cancer.
    Sarosdy MF, Lamm DL.
    J Urol; 1989 Sep; 142(3):719-22. PubMed ID: 2769847
    [Abstract] [Full Text] [Related]

  • 17. Adverse impact of fibrin clot inhibitors on intravesical bacillus Calmette-Guerin therapy for superficial bladder tumors.
    Hudson MA, Yuan JJ, Catalona WJ, Ratliff TL.
    J Urol; 1990 Dec; 144(6):1362-4. PubMed ID: 2231927
    [Abstract] [Full Text] [Related]

  • 18. Rationale for intravesical chemotherapy in the treatment and prophylaxis of superficial transitional cell carcinoma.
    Soloway MS, Jordan AM, Murphy WM.
    Prog Clin Biol Res; 1989 Dec; 310():215-36. PubMed ID: 2505268
    [Abstract] [Full Text] [Related]

  • 19. Bacillus Calmette-Guerin therapy for high risk stage T1 superficial bladder cancer.
    Eure GR, Cundiff MR, Schellhammer PF.
    J Urol; 1992 Feb; 147(2):376-9. PubMed ID: 1732597
    [Abstract] [Full Text] [Related]

  • 20. Update on the Dutch Cooperative Trial: mitomycin versus bacillus Calmette-Guérin-Tice versus bacillus Calmette-Guérin RIVM in the treatment of patients with pTA-pT1 papillary carcinoma and carcinoma in situ of the urinary bladder. Dutch South East Cooperative Urological Group.
    Witjes WP, Witjes JA, Oosterhof GO, Debruyne MJ.
    Semin Urol Oncol; 1996 Feb; 14(1 Suppl 1):10-6. PubMed ID: 8727805
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.